B29K2201/00

ORGANIZATIONAL APPARATUS WITH EXPANDING FOAM
20230030137 · 2023-02-02 · ·

A design, material, and process of manufacturing an organizational apparatus, e.g., an organizational bin, made from expanding-foam. In some examples, the bin includes four walls and a base forming an interior cavity that is configured to receive items to be organized, stored, or transported, e.g., shoes, or dirty or wet items. In some examples, the material used is a plant-based or bio-based Ethylene-vinyl Acetate (EVA) expansion-foam.

Resin composition for shaping material of fused deposition modeling method-3D printer and filamentary molded body thereof

The present invention provides a resin composition having high heat-resisting properties, with which a shaping can be performed in accordance with designed sizes using a fused deposition modeling method-3D printer, and from which a shaped object having a small warpage and small changes in sizes due to water can be obtained. The present invention relates to a resin composition for a shaping material of a fused deposition modeling method-3D printer, comprising cellulose fibers in a polyamide.

Thermoplastic resin composition, method of producing thermoplastic resin composition, molded article of cellulose-reinforced resin, and method of producing molded article of cellulose-reinforced resin

A method of producing a thermoplastic resin composition containing a thermoplastic synthetic resin and a cellulose, in which at least one type of the thermoplastic synthetic resin is a resin having a group containing a partial structure of an acid anhydride in the polymer molecule; a molded article of a cellulose-reinforced resin; and a method of producing a molded article of a cellulose-reinforced resin.

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.

NANOCOMPOSITE ELASTOMERS
20170333602 · 2017-11-23 ·

A composite material comprising an elastomer and nanocellulose. The nanocellulose may comprise a nanocellulose material derived from plants having C4 leaf anatomy, or a nanocellulose material derived from a plant material having a lesser amount of lignin than hemi-cellulose, or a nanocellulose having a hemicellulose content of from 25% to 55% by weight of the nanocellulose material, or a nanocellulose comprising nanofibrils having a diameter of up to 5 nm, or a nanocellulose comprising nanocellulose material of plant origin comprising nanocellulose particles or fibres having an aspect ratio of at least 250, or the composite material having a stiffness of not greater than 2.5 times the stiffness of the elastomer without the nanocellulose material being present, or the nanocellulose particles or fibres being derived from a plant material having a hemicellulose content of 30% or higher (w/w). The nanocellulose may be derived from arid Spinifex.

COMPOSITE MATERIALS COMPRISING CELLULOSE FILAMENTS AND FILLERS AND METHODS FOR THE PREPARATION THEREOF

The present disclosure relates to composite materials comprising a resin and at least one sheet that comprise optionally cellulose filaments (CF), fillers and optionally reinforcing fibers as well as methods for the preparation thereof. The methods comprise impregnating the sheets comprising the cellulose filaments, fillers and optionally the reinforcing fibers or a stack thereof with resin. The composite materials can optionally comprise at least one other sheet, the at least one other sheet being different from the at least one sheet and comprising fibers chosen from wood pulp, fiberglass, natural fibers and mixtures thereof. The sheet can also be in the form of a panel of a preform.

SUPPORT MATERIAL, SUPPORT MATERIAL POWDER, AND METHOD FOR PRODUCING THREE-DIMENSIONAL OBJECT USING SAME

A support material contains at least one member selected from the group consisting of low molecular weight saccharides, polyvinyl alcohols, and polyalkylene glycols; non-water-soluble cellulose fibers; and a water-soluble cellulose derivative.

FIBROUS CELLULOSE COMPOSITE RESIN AND METHOD FOR MANUFACTURING THE SAME
20220049071 · 2022-02-17 · ·

To provide a fibrous cellulose composite resin having excellent strength, particularly excellent flexural modulus, and having no coloring problem, and a method for manufacturing the same. A fibrous cellulose composite resin contains: microfiber cellulose having an average fiber width of 0.1 μm or more; a resin; and a polybasic acid salt. In addition, the raw material fibers are defibrated into microfiber cellulose within a range where the microfiber cellulose has an average fiber width of 0.1 μm or more, and this microfiber cellulose, a resin, and a polybasic acid salt are kneaded to manufacture a fibrous cellulose composite resin.

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.

METHOD FOR CONTROLLING SHRINKAGE OF A COMPOSITE
20170267819 · 2017-09-21 ·

In a method for controlling shrinkage of a composite, a dried hydrophobically modified cellulose-based fiber is exposed to a slow acting resin system having a first curing time. An excess amount of the slow acting resin system is removed to separate out the pre-wetted hydrophobically modified cellulose-based fiber. The pre-wetted hydrophobically modified cellulose-based fiber is mixed with a fast acting resin system to form a mixture. The fast acting resin system has a second curing time that is less than the first curing time. The mixture is molded at a predetermined temperature. The fast acting resin system is cured prior to the slow acting resin system, and the slow acting resin system flows into free space within the curing fast acting resin system prior to the slow acting resin system being cured.